Virginia Braman

643 total citations
21 papers, 478 citations indexed

About

Virginia Braman is a scholar working on Oncology, Periodontics and Immunology. According to data from OpenAlex, Virginia Braman has authored 21 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Periodontics and 5 papers in Immunology. Recurrent topics in Virginia Braman's work include Oral microbiology and periodontitis research (5 papers), Peptidase Inhibition and Analysis (4 papers) and Antimicrobial Peptides and Activities (3 papers). Virginia Braman is often cited by papers focused on Oral microbiology and periodontitis research (5 papers), Peptidase Inhibition and Analysis (4 papers) and Antimicrobial Peptides and Activities (3 papers). Virginia Braman collaborates with scholars based in United States, United Kingdom and Switzerland. Virginia Braman's co-authors include Phillip Friden, David W. Paquette, Ray Williams, Joseph M. Massaro, David M. Simpson, Serge Dibart, Ralph B. D’Agostino, Thomas E. Van Dyke, Livingston Van De Water and LuAnn Sabounjian and has published in prestigious journals such as Journal of Controlled Release, The American Journal of Cardiology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Virginia Braman

21 papers receiving 443 citations

Peers

Virginia Braman

MICRO

IMMUN

PERIO

Dezhi Li China

Min Hyung Jung South Korea

R Niedner Germany

Javier Millán Soria Spain

Xuxia Wang China

Chang Zeng United States

Michael Goldberg United States

Maria M. Stollenwerk Sweden

Fábio Trindade Portugal

Young Woo Park South Korea

Dezhi Li China

Virginia Braman

223 ×1.8

16 ×0.2

MICRO

53 ×0.6

53 ×0.7

IMMUN

8 ×0.2

PERIO

Citations per year, relative to Virginia Braman Virginia Braman (= 1×) peers Dezhi Li

Countries citing papers authored by Virginia Braman

Since Specialization

Citations

This map shows the geographic impact of Virginia Braman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginia Braman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginia Braman more than expected).

Fields of papers citing papers by Virginia Braman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginia Braman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginia Braman. The network helps show where Virginia Braman may publish in the future.

Co-authorship network of co-authors of Virginia Braman

This figure shows the co-authorship network connecting the top 25 collaborators of Virginia Braman. A scholar is included among the top collaborators of Virginia Braman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginia Braman. Virginia Braman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

King, Brett, Natasha Atanaskova Mesinkovska, Paradi Mirmirani, et al.. (2022). Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata. Journal of the American Academy of Dermatology. 87(2). 306–313. 56 indexed citations

Uttamsingh, Vinita, C.J. Hamilton, Ara M. Aslanian, et al.. (2018). 1060 JAK inhibitor CTP-543: Modeled exposure-response profile suggests improved therapeutic window. Journal of Investigative Dermatology. 138(5). S180–S180. 1 indexed citations

Harbeson, Scott L., Adam J. Morgan, Ara M. Aslanian, et al.. (2017). Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development. Journal of Pharmacology and Experimental Therapeutics. 362(2). 359–367. 54 indexed citations

Uddin, Nizam, et al.. (2016). WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco ® in Phase I clinical studies. Journal of Cystic Fibrosis. 15. S22–S22. 8 indexed citations

Sabounjian, LuAnn, Philip B. Graham, Lijun Wu, et al.. (2015). A First‐in‐Patient, Multicenter, Double‐Blind, 2‐Arm, Placebo‐Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP‐499, in Chronic Kidney Disease. Clinical Pharmacology in Drug Development. 5(4). 314–325. 22 indexed citations

Wu, Lijun, et al.. (2014). Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis. Journal of Chromatography B. 963. 1–9. 11 indexed citations

Braman, Virginia, Philip B. Graham, Changfu Cheng, et al.. (2013). A Randomized Phase I Evaluation of CTP‐499, a Novel Deuterium‐Containing Drug Candidate for Diabetic Nephropathy. Clinical Pharmacology in Drug Development. 2(1). 53–66. 27 indexed citations

Sabounjian, LuAnn, James E. Shipley, Virginia Braman, et al.. (2012). Design and Rationale for Randomized, Doubleblind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Patients With Diabetic Nephropathy (DN). Advances in Chronic Kidney Disease. 19(2). 123–123. 2 indexed citations

Carson, Peter E., S. William Tam, Jalal K. Ghali, et al.. (2009). Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. Journal of Cardiac Failure. 15(10). 835–842. 43 indexed citations

10.

Yancy, Clyde W., Jalal K. Ghali, Virginia Braman, et al.. (2007). Evidence for the Continued Safety and Tolerability of Fixed-Dose Isosorbide Dinitrate/Hydralazine in Patients With Chronic Heart Failure (the Extension to African-American Heart Failure Trial). The American Journal of Cardiology. 100(4). 684–689. 7 indexed citations

11.

Yancy, Clyde W., Jalal K. Ghali, Virginia Braman, Michael L. Sabolinski, & Manuel Worcel. (2006). Results of the Extension to A-HeFT [X-A-HeFT] Support the Continued Safety and Tolerability of Fixed-Dose Isosorbide Dinitrate/Hydralazine (ISDN/HYD). Journal of Cardiac Failure. 12(6). S80–S80. 2 indexed citations

12.

Dyke, Thomas E. Van, David W. Paquette, Sara Grossi, et al.. (2002). Clinical and microbial evaluation of a histatin‐containing mouthrinse in humans with experimental gingivitis: a phase‐2 multi‐center study. Journal Of Clinical Periodontology. 29(2). 168–176. 30 indexed citations

13.

Paquette, David W., David M. Simpson, Phillip Friden, Virginia Braman, & Ray Williams. (2002). Safety and clinical effects of topical histatin gels in humans with experimental gingivitis. Journal Of Clinical Periodontology. 29(12). 1051–1058. 46 indexed citations

14.

Massaro, Joseph M., Phillip Friden, Virginia Braman, et al.. (2001). Clinical and microbial evaluation of a histatin‐containing mouthrinse in humans with experimental gingivitis. Journal Of Clinical Periodontology. 28(5). 404–410. 38 indexed citations

15.

Suvan, Jean, Niklaus P. Lang, Andrea Mombelli, et al.. (2001). Phase 1 evaluation of a local delivery device releasing silver ions in periodontal pockets: safety, pharmacokinetics and bioavailability. Journal of Periodontal Research. 36(3). 187–193. 12 indexed citations

16.

Bromberg, Lev, Virginia Braman, David M. Rothstein, et al.. (2000). Sustained release of silver from periodontal wafers for treatment of periodontitis. Journal of Controlled Release. 68(1). 63–72. 31 indexed citations

17.

Longo, Dan L., P L Duffey, JG Gribben, et al.. (2000). Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.. PubMed. 6(3). 146–50. 26 indexed citations

18.

Shefner, Jeremy M., Patrick Y. Wen, Virginia Braman, et al.. (1994). Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. International Journal of Cancer. 57(S8). 57–59. 22 indexed citations

19.

Water, Livingston Van De, et al.. (1988). Alteration of fibronectin receptors (integrins) in phorbol ester-treated human promonocytic leukemia cells.. PubMed. 48(20). 5730–7. 24 indexed citations

20.

Jonak, Zdenka, Virginia Braman, & Roger H. Kennett. (1984). Production of Continuous Mouse Plasma Cell Lines by Transfection with Human Leukemia DNA. Hybridoma. 3(2). 107–118. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact